Explore
Validate
Learn
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 313603 - Provider product page
- Provider
- BioLegend
- Proper citation
- BioLegend Cat#313603, RRID:AB_345297
- Product name
- Biotin anti-human/mouse CD49f
- Antibody type
- Monoclonal
- Antigen
- Mouse mammary tumor cells
- Description
- CD49f is a 120 kD integrin family member, also known as VLA-6 α chain and α6 integrin subunit. CD49f associates with either integrin β1 (CD29) or integrin β4 (CD104) to form receptors (VLA-6 or α6β4 complex) for laminin and kalinin. CD49f is expressed on platelets, monocytes, T cells, placental trophoblasts, epithelial and endothelial cells. CD49f is involved in adhesion and can act as a co-stimulatory molecule for T cell activation and proliferation. The GoH3 antibody has been reported to block laminin binding in vitro and to block integrin α6 function in vivo.
- Reactivity
- Human, Mouse, Bovine, Canine, Feline, Horse, Porcine, Rabbit, Sheep, Simian
- Host
- Rat
- Conjugate
- Biotin
- Isotype
- IgG
- Vial size
- 25 µg
- Concentration
- 0.5 mg/ml
- Storage
- The antibody solution should be stored undiluted at 4°C. Do not freeze.
Submitted references Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells.
Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo.
Differential requirement of mTOR in postmitotic tissues and tumorigenesis.
Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.
Reduced migration, altered matrix and enhanced TGFbeta1 signaling are signatures of mouse keratinocytes lacking Sdc1.
Jo M, Eastman BM, Webb DL, Stoletov K, Klemke R, Gonias SL
Cancer research 2010 Nov 1;70(21):8948-58
Cancer research 2010 Nov 1;70(21):8948-58
Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo.
Xu T, Xu Y, Liao CP, Lau R, Goldkorn A
Molecular cancer therapeutics 2010 Feb;9(2):438-49
Molecular cancer therapeutics 2010 Feb;9(2):438-49
Differential requirement of mTOR in postmitotic tissues and tumorigenesis.
Nardella C, Carracedo A, Alimonti A, Hobbs RM, Clohessy JG, Chen Z, Egia A, Fornari A, Fiorentino M, Loda M, Kozma SC, Thomas G, Cordon-Cardo C, Pandolfi PP
Science signaling 2009 Jan 27;2(55):ra2
Science signaling 2009 Jan 27;2(55):ra2
Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.
Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA
Proceedings of the National Academy of Sciences of the United States of America 2008 Apr 15;105(15):5774-9
Proceedings of the National Academy of Sciences of the United States of America 2008 Apr 15;105(15):5774-9
Reduced migration, altered matrix and enhanced TGFbeta1 signaling are signatures of mouse keratinocytes lacking Sdc1.
Stepp MA, Liu Y, Pal-Ghosh S, Jurjus RA, Tadvalkar G, Sekaran A, Losicco K, Jiang L, Larsen M, Li L, Yuspa SH
Journal of cell science 2007 Aug 15;120(Pt 16):2851-63
Journal of cell science 2007 Aug 15;120(Pt 16):2851-63
No comments: Submit comment
Supportive validation
- Submitted by
- BioLegend (provider)
- Main image
- Experimental details
- C57BL/6 mouse splenocytes stained with biotinylated GoH3, followed by Sav-PE
- Conjugate
- Biotin
